The anti-inflammatory and immunological properties of SGLT-2 inhibitors.
Cytokines
Immune cells
Immune system
Inflammation
SGLT-2 inhibitors
Journal
Journal of endocrinological investigation
ISSN: 1720-8386
Titre abrégé: J Endocrinol Invest
Pays: Italy
ID NLM: 7806594
Informations de publication
Date de publication:
Dec 2023
Dec 2023
Historique:
received:
17
04
2023
accepted:
18
07
2023
medline:
10
11
2023
pubmed:
3
8
2023
entrez:
3
8
2023
Statut:
ppublish
Résumé
Sodium-glucose cotransporter-2 inhibitors (SGLT-2i) are antidiabetic oral drugs that act on proximal renal tubules promoting renal glucose excretion. Although SGLT-2i belong to the class of hypoglycemic agents, in the last years great interest has emerged in studying their pleiotropic effects, beyond their ability to lower glucose levels. In this review we are describing the anti-inflammatory and immunological properties of SGLT-2i; furthermore, we are addressing how the mechanisms associated with the aforementioned anti-inflammatory properties may contribute to the beneficial effects of SGLT-2i in diabetes. A systematic search was undertaken for studies related the properties of SGLT-2i in reducing the inflammatory milieu of acute and chronic disease by acting on the immune system, independently by glycemia. Recently, some data described the anti-inflammatory and immunological properties of SGLT-2 in both pre-clinical and clinical studies. Numerous data confirmed the cardio- and -renal protective effects of SGLT-2i in patients with heart failure and kidney diseases, with or without diabetes. SGLT-2i are promising drugs with anti-inflammatory and immunological properties. Despite the mechanism of action of SGLT-2i is not fully understood, these drugs demonstrated anti-inflammatory effects, which may help in keeping under control the variety of complications associated with diabetes.
Sections du résumé
BACKGROUND
BACKGROUND
Sodium-glucose cotransporter-2 inhibitors (SGLT-2i) are antidiabetic oral drugs that act on proximal renal tubules promoting renal glucose excretion. Although SGLT-2i belong to the class of hypoglycemic agents, in the last years great interest has emerged in studying their pleiotropic effects, beyond their ability to lower glucose levels.
PURPOSE
OBJECTIVE
In this review we are describing the anti-inflammatory and immunological properties of SGLT-2i; furthermore, we are addressing how the mechanisms associated with the aforementioned anti-inflammatory properties may contribute to the beneficial effects of SGLT-2i in diabetes.
METHODS
METHODS
A systematic search was undertaken for studies related the properties of SGLT-2i in reducing the inflammatory milieu of acute and chronic disease by acting on the immune system, independently by glycemia.
RESULTS
RESULTS
Recently, some data described the anti-inflammatory and immunological properties of SGLT-2 in both pre-clinical and clinical studies. Numerous data confirmed the cardio- and -renal protective effects of SGLT-2i in patients with heart failure and kidney diseases, with or without diabetes.
CONCLUSIONS
CONCLUSIONS
SGLT-2i are promising drugs with anti-inflammatory and immunological properties. Despite the mechanism of action of SGLT-2i is not fully understood, these drugs demonstrated anti-inflammatory effects, which may help in keeping under control the variety of complications associated with diabetes.
Identifiants
pubmed: 37535237
doi: 10.1007/s40618-023-02162-9
pii: 10.1007/s40618-023-02162-9
doi:
Substances chimiques
Sodium-Glucose Transporter 2 Inhibitors
0
Hypoglycemic Agents
0
Anti-Inflammatory Agents
0
Glucose
IY9XDZ35W2
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
2445-2452Informations de copyright
© 2023. The Author(s), under exclusive licence to Italian Society of Endocrinology (SIE).
Références
Bendotti G, Montefusco L, Lunati ME et al (2022) The anti-inflammatory and immunological properties of GLP-1 receptor agonists. Pharmacol Res. https://doi.org/10.1016/j.phrs.2022.106320
doi: 10.1016/j.phrs.2022.106320
pubmed: 35738455
Zelniker TA, Braunwald E (2020) Mechanisms of cardiorenal effects of sodium–glucose cotransporter 2 inhibitors. JACC 75:13. https://doi.org/10.1016/j.jacc.2019.11.031
doi: 10.1016/j.jacc.2019.11.031
Lunati ME, Cimino V, Gandolfi A, Fiorina P (2022) SGLT2-inhibitors are effective and safe in the elderly: The SOLD study. Pharmacol Res. https://doi.org/10.1016/j.phrs.2022.106396
doi: 10.1016/j.phrs.2022.106396
pubmed: 35970329
Lazzaroni E (2022) Dapagliflozin acutely improves kidney function in type 2 diabetes mellitus. The PRECARE study. Pharmacol Res. https://doi.org/10.1016/j.phrs.2022.106374
doi: 10.1016/j.phrs.2022.106374
pubmed: 35908663
Schlosser J, Umpierrez G, Weinstock R et al (2022) Standards of Medical Care in Diabetes. Diabetes Care 45:S125–S143. https://doi.org/10.2337/dc22-S009
doi: 10.2337/dc22-S009
Francese R, Fiorina P (2010) Immunological and regenerative properties of cord blood stem cells. Clin Immunol. https://doi.org/10.1016/j.clim.2010.04.010
doi: 10.1016/j.clim.2010.04.010
pubmed: 20447870
Williams MD, Nadler JL (2007) Inflammatory mechanisms of diabetic complications. Curr Diab Rep 7:242–248. https://doi.org/10.1007/s11892-007-0038-y
doi: 10.1007/s11892-007-0038-y
pubmed: 17547842
Tsalamandris S, Antonopoulos AS, Oikonomou E et al (2019) The role of inflammation in diabetes: current concepts and future perspectives. Eur Cardiol 14:50–59. https://doi.org/10.15420/ecr.2018.33.1
doi: 10.15420/ecr.2018.33.1
pubmed: 31131037
pmcid: 6523054
Fiorina P, Dell’Aglio P (1996) Impaired nocturnal melatonin excretion and changes of immunological status in ischaemic stroke patients. The Lancet. https://doi.org/10.1016/s0140-6736(96)91246-5
doi: 10.1016/s0140-6736(96)91246-5
Feijóo-Bandín S, Aragón-Herrera A, Otero-Santiago M et al (2022) Role of sodium–glucose co-transporter 2 inhibitors in the regulation of inflammatory processes in animal models. Int J Mol Sci. https://doi.org/10.3390/ijms23105634
doi: 10.3390/ijms23105634
pubmed: 35628443
pmcid: 9144929
Bray JJH (2020) A systematic review examining the effects of sodium–glucose cotransporter-2 inhibitors (SGLT2is) on biomarkers of inflammation and oxidative stress. Diabetes Res Clin Pract. https://doi.org/10.1016/j.diabres.2020.108368
doi: 10.1016/j.diabres.2020.108368
pubmed: 32800932
Fiorentino TV, Prioletta A, Zuo P, Folli F (2013) Hyperglycemia-induced oxidative stress and its role in diabetes mellitus related cardiovascular diseases. Curr Pharm Des. https://doi.org/10.2174/1381612811319320005
doi: 10.2174/1381612811319320005
pubmed: 23448484
Folli F, Corradi D, Fanti P et al (2011) The role of oxidative stress in the pathogenesis of type 2 diabetes mellitus micro- and macrovascular complications: avenues for a mechanistic-based therapeutic approach. Curr Diabetes Rev. https://doi.org/10.2174/157339911797415585
doi: 10.2174/157339911797415585
pubmed: 21838680
Cerami A (1985) Protein glycosylation and the pathogenesis of atherosclerosis. Metabolism. https://doi.org/10.1016/s0026-0495(85)80008-1
doi: 10.1016/s0026-0495(85)80008-1
pubmed: 3906359
Brownlee M (1995) Advanced protein glycosylation in diabetes and aging. Annu Rev Med. https://doi.org/10.1146/annurev.med.46.1.223
doi: 10.1146/annurev.med.46.1.223
pubmed: 7598459
Folli F, Guzzi V, Perego L et al (2010) Proteomics reveals novel oxidative and glycolytic mechanisms in type 1 diabetic patients’ skin which are normalized by kidney-pancreas transplantation. PLoS One. https://doi.org/10.1371/journal.pone.0009923
doi: 10.1371/journal.pone.0009923
pubmed: 20360867
pmcid: 2848014
Pawlos A, Broncel M, Woźniak E, Gorzelak-Pabiś P (2021) Neuroprotective effect of SGLT2 inhibitors. Molecules 26:16. https://doi.org/10.3390/molecules26237213
doi: 10.3390/molecules26237213
Cowie MR (2020) SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control. Nat Rev Cardiol. https://doi.org/10.1038/s41569-020-0406-8
doi: 10.1038/s41569-020-0406-8
pubmed: 32665641
Nasiri-Ansari N, Nikolopoulou C, Papoutsi K et al (2021) Empagliflozin attenuates non-alcoholic fatty liver disease (NAFLD) in high fat diet fed ApoE(-/-) mice by activating autophagy and reducing ER stress and apoptosis. Int J Mol Sci. https://doi.org/10.3390/ijms22020818
doi: 10.3390/ijms22020818
pubmed: 33467546
pmcid: 7829901
Kondo H, Akoumianakis I, Badi I et al (2020) Effects of canagliflozin on human myocardial redox signalling: clinical implications. Eur Heart J 42:4947–4960. https://doi.org/10.1093/eurheartj/ehab420
doi: 10.1093/eurheartj/ehab420
Quagliariello V (2021) The SGLT-2 inhibitor empagliflozin improves myocardial strain, reduces cardiac fibrosis and pro-inflammatory cytokines in non-diabetic mice treated with doxorubicin. Cardiovasc Diabetol 150:20. https://doi.org/10.1186/s12933-021-01346-y
doi: 10.1186/s12933-021-01346-y
Diaz-Rodriguez E (2018) Novel effects of dapagliflozin on epicardial adipose tissue with insulin resistance, high levels of inflammatory chemokines production and low differentiation ability. Cardiovasc Res. https://doi.org/10.1093/cvr/cvx186
doi: 10.1093/cvr/cvx186
pubmed: 29016744
Iacobellis G (2022) Cardiovascular risk reduction throughout GLP-1 receptor agonist and SGLT2 inhibitor modulation of epicardial fat. J Endocrinol Invest. https://doi.org/10.1007/s40618-021-01687-1
doi: 10.1007/s40618-021-01687-1
pubmed: 34643917
Uthman L, Homayr A, Kerindongo R et al (2019) Empagliflozin and dapagliflozin Reduce ROS generation and restore NO bioavailability in tumor necrosis factor α-stimulated human coronary arterial endothelial cells. Cell Physiol Biochem 53:865–886. https://doi.org/10.33594/000000178
doi: 10.33594/000000178
pubmed: 31724838
Sukhanov S (2021) The SGLT2 inhibitor Empagliflozin attenuates interleukin-17A-induced human aortic smooth muscle cell proliferation and migration by targeting TRAF3IP2/ROS/NLRP3/Caspase-1-dependent IL-1β and IL-18 secretion. Cell Signal. https://doi.org/10.1016/j.cellsig.2020.109825
doi: 10.1016/j.cellsig.2020.109825
pubmed: 33160017
Jongs N (2021) Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial. Lancet Diabetes Endocrinol. https://doi.org/10.1016/S2213-8587(21)00243-6
doi: 10.1016/S2213-8587(21)00243-6
pubmed: 34856173
Sen T, Heerspink HJL (2021) A kidney perspective on the mechanism of action of sodium glucose co-transporter 2 inhibitors. Cell Metab. https://doi.org/10.1016/j.cmet.2021.02.016
doi: 10.1016/j.cmet.2021.02.016
pubmed: 33691091
Perkovic V, Jardine MJ, Neal B et al (2019) Canagliflozin and Renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. https://doi.org/10.1056/NEJMoa1811744
doi: 10.1056/NEJMoa1811744
pubmed: 31509685
The EMPA-KIDNEY Collaborative Group (2022) Empagliflozin in patients with chronic kidney disease. N Engl J Med. https://doi.org/10.1056/NEJMoa2204233
doi: 10.1056/NEJMoa2204233
pmcid: 7614055
Astorri E, Fiorina P, Gavaruzzi G et al (1997) Left ventricular function in insulin-dependent and in non-insulin-dependent diabetic patients: radionuclide assessment. Cardiology. https://doi.org/10.1159/000177322
doi: 10.1159/000177322
pubmed: 9096915
Perseghin G (2005) Cross-sectional assessment of the effect of kidney and kidney-pancreas transplantation on resting left ventricular energy metabolism in type 1 diabetic-uremic patients. Pancreas Transplant 46:8. https://doi.org/10.1016/j.jacc.2005.05.075
doi: 10.1016/j.jacc.2005.05.075
McMurray JJV, Solomon SD, Inzucchi SE et al (2019) Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. https://doi.org/10.1056/NEJMoa1911303
doi: 10.1056/NEJMoa1911303
pubmed: 31535829
Anker SD, Butler J, Filippatos G, EMPEROR-Preserved Trial Investigators (2021) Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. https://doi.org/10.1056/NEJMoa2107038
doi: 10.1056/NEJMoa2107038
pubmed: 34449189
Nasr MB, Tezza S, D’Addio F et al (2018) PD-L1 genetic overexpression or pharmacological restoration in hematopoietic stem and progenitor cells reverses autoimmune diabetes. Sci Transl Med. https://doi.org/10.1126/scitranslmed.aam7543
doi: 10.1126/scitranslmed.aam7543
Niewczas MA, Pavkov ME, Skupien J et al (2019) A signature of circulating inflammatory proteins and development of end stage renal disease in diabetes. Nat Me. https://doi.org/10.1038/s41591-019-0415-5
doi: 10.1038/s41591-019-0415-5
Xu J, Kitada M, Ogura Y et al (2021) Dapagliflozin restores impaired autophagy and suppresses inflammation in high glucose-treated HK-2 cells. Cells 10:1457. https://doi.org/10.3390/cells10061457
doi: 10.3390/cells10061457
pubmed: 34200774
pmcid: 8230404
Das NA (2020) Empagliflozin reduces high glucose-induced oxidative stress and miR-21-dependent TRAF3IP2 induction and RECK suppression, and inhibits human renal proximal tubular epithelial cell migration and epithelial-to-mesenchymal transition. Cellular Signaling. https://doi.org/10.1016/j.cellsig.2019.109506
doi: 10.1016/j.cellsig.2019.109506
Donnini S, Berezin AE, Ferretti E (2022) Cell-target-specific anti-inflammatory effect of empagliflozin: in vitro evidence in human cardiomyocytes. Front Mol Biosci 9:7. https://doi.org/10.3389/fmolb.2022.879522
doi: 10.3389/fmolb.2022.879522
Kolijn D (2020) Empagliflozin improves endothelial and cardiomyocyte function in human heart failure with preserved ejection fraction via reduced pro-inflammatory-oxidative pathways and protein kinase Gα oxidation. Cardiovasc Res. https://doi.org/10.1093/cvr/cvaa123
doi: 10.1093/cvr/cvaa123
El-Shafey M (2022) Role of dapagliflozin and liraglutide on diabetes-induced cardiomyopathy in rats: implication of oxidative stress, inflammation, and apoptosis. Front Endocrinol 13:14. https://doi.org/10.3389/fendo.2022.862394
doi: 10.3389/fendo.2022.862394
Lee T-M (2017) Dapagliflozin, a selective SGLT2 Inhibitor, attenuated cardiac fibrosis by regulating the macrophage polarization via STAT3 signaling in infarcted rat hearts. Free Rad Biol Med. https://doi.org/10.1016/j.freeradbiomed.2017.01.035
doi: 10.1016/j.freeradbiomed.2017.01.035
pubmed: 29233794
Ye Y (2017) SGLT-2 inhibition with dapagliflozin reduces the activation of the Nlrp3/ASC inflammasome and attenuates the development of diabetic cardiomyopathy in mice with type 2 diabetes. Further augmentation of the effects with saxagliptin, a DPP4 inhibitor. Cardiovasc Drugs Ther. https://doi.org/10.1007/s10557-017-6725-2
doi: 10.1007/s10557-017-6725-2
pubmed: 29185103
Wang D, Zhang Z, Si Z et al (2021) Dapagliflozin reverses the imbalance of T helper 17 and T regulatory cells by inhibiting SGK1 in a mouse model of diabetic kidney disease. FEBS Open Bio. https://doi.org/10.1002/2211-5463.13147
doi: 10.1002/2211-5463.13147
pubmed: 34856073
pmcid: 8727938
Liu H, Wei P, Fu W et al (2022) Dapagliflozin ameliorates the formation and progression of experimental abdominal aortic aneurysms by reducing aortic inflammation in mice. Oxid Med Cell Longev. https://doi.org/10.1155/2022/8502059
doi: 10.1155/2022/8502059
pubmed: 36620085
pmcid: 9822743
Jaikumkao K (2018) Dapagliflozin, a SGLT2 inhibitor, slows the progression of renal complications through the suppression of renal inflammation, ER stress, and apoptosis in pre-diabetic rats. Diabetes Obes Metab. https://doi.org/10.1111/dom.13441
doi: 10.1111/dom.13441
pubmed: 29923295
ElMahdy MK (2020) Potential anti-inflammatory effect of dapagliflozin in HCHF diet- induced fatty liver degeneration through inhibition of TNF-α, IL-1β, and IL-18 in rat liver. Int Immunopharmacol. https://doi.org/10.1016/j.intimp.2020.106730
doi: 10.1016/j.intimp.2020.106730
pubmed: 32599319
Radlinger B (2020) Cardioprotective effects of short-term empagliflozin treatment in db/db mice. Sci Rep 10:10. https://doi.org/10.1038/s41598-020-76698-8
doi: 10.1038/s41598-020-76698-8
Zhang Q-Q, Li G-Q, Mao X-M (2020) Empagliflozin improves chronic hypercortisolism-induced abnormal myocardial structure and cardiac function in mice. Ther Adv Chron Disease. https://doi.org/10.1177/2040622320974833
doi: 10.1177/2040622320974833
Yan P (2022) Dapagliflozin alleviates coxsackievirus B3-induced acute viral myocarditis by regulating the macrophage polarization through stat3-related pathways. Inflammation. https://doi.org/10.1007/s10753-022-01677-2
doi: 10.1007/s10753-022-01677-2
pubmed: 36526899
Xu L, Nagata N, Nagashimada M et al (2017) SGLT2 inhibition by empagliflozin promotes fat utilization and browning and attenuates inflammation and insulin resistance by polarizing M2 macrophages in diet-induced obese mice. EBioMedicine. https://doi.org/10.1016/j.ebiom.2017.05.028
doi: 10.1016/j.ebiom.2017.05.028
pubmed: 29191560
pmcid: 5832625
Xu L, Nagata N, Chen G et al (2019) Empagliflozin reverses obesity and insulin resistance through fat browning and alternative macrophage activation in mice fed a high-fat diet. BMJ Open Diab Res Care. https://doi.org/10.1136/bmjdrc-2019-000783
doi: 10.1136/bmjdrc-2019-000783
pubmed: 31749970
pmcid: 6827766
Meng Z (2021) The SGLT2 inhibitor empagliflozin negatively regulates IL-17/IL-23 axis-mediated inflammatory responses in T2DM with NAFLD via the AMPK/mTOR/autophagy pathway. Int Immunopharmacol. https://doi.org/10.1016/j.intimp.2021.107492
doi: 10.1016/j.intimp.2021.107492
pubmed: 34933161
Tomita I (2020) SGLT2 inhibition mediates protection from diabetic kidney disease by promoting ketone body-induced mTORC1 inhibition. Cell Metab. https://doi.org/10.1016/j.cmet.2020.06.020
doi: 10.1016/j.cmet.2020.06.020
pubmed: 32726607
Park HJ (2019) Empagliflozin and dulaglutide are effective against obesity-induced airway hyperresponsiveness and fibrosis in a murine model. Sci Rep. https://doi.org/10.1038/s41598-019-51648-1
doi: 10.1038/s41598-019-51648-1
pubmed: 31892695
pmcid: 6938486
Chen S, Wang Q, Christodoulou A et al (2023) Sodium glucose cotransporter-2 inhibitor empagliflozin reduces infarct size independently of sodium glucose cotransporter-2. Circulation. https://doi.org/10.1161/CIRCULATIONAHA.122.061688
doi: 10.1161/CIRCULATIONAHA.122.061688
pubmed: 37937463
pmcid: 7614572
Lin F (2020) Canagliflozin alleviates LPS-induced acute lung injury by modulating alveolar macrophage polarization. Int Immunopharmacol. https://doi.org/10.1016/j.intimp.2020.106969
doi: 10.1016/j.intimp.2020.106969
pubmed: 33383448
pmcid: 7518179
Nasiri-Ansari Ν (2018) Canagliflozin attenuates the progression of atherosclerosis and inflammation process in APOE knockout mice. Cardiovasc Diabetol. https://doi.org/10.1186/s12933-018-0749-1
doi: 10.1186/s12933-018-0749-1
pubmed: 30049285
Ganbaatar B (2020) Empagliflozin ameliorates endothelial dysfunction and suppresses atherogenesis in diabetic apolipoprotein E-deficient mice. Eur J Pharmacol. https://doi.org/10.1016/j.ejphar.2020.173040
doi: 10.1016/j.ejphar.2020.173040
pubmed: 32114052
Leng W, Ouyang X, Lei X et al (2016) The SGLT-2 inhibitor dapagliflozin has a therapeutic effect on atherosclerosis in diabetic ApoE−/− Mice. Mediators Inflamm. https://doi.org/10.1155/2016/6305735
doi: 10.1155/2016/6305735
pubmed: 28104929
pmcid: 5220517
Ridker PM, Everett BM, Thuren T, the CANTOS Trial Group (2017) Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. https://doi.org/10.1056/NEJMoa1707914
doi: 10.1056/NEJMoa1707914
Loretelli C, Rocchio F, D’Addio F, Fiorina P (2021) The IL-8-CXCR1/2 axis contributes to diabetic kidney disease. Cell Metab. https://doi.org/10.1016/j.metabol.2021.154804
doi: 10.1016/j.metabol.2021.154804
Kip KE, Marroquin OC, Shaw LJ et al (2005) Global inflammation predicts cardiovascular risk in women: a report from the Women’s Ischemia Syndrome Evaluation (WISE) study. Am Heart J. https://doi.org/10.1016/j.ahj.2005.02.002
doi: 10.1016/j.ahj.2005.02.002
pubmed: 16290958
Bonanni A (2022) Molecular hallmarks of ischemia with non-obstructive coronary arteries: the “INOCA versus obstructive CCS” challenge. J Clin Med. https://doi.org/10.3390/jcm11061711
doi: 10.3390/jcm11061711
pubmed: 36233830
pmcid: 9573406
Dekkers CCJ, Petrykiv S, Laverman GD et al (2018) Effects of the SGLT-2 inhibitor dapagliflozin on glomerular and tubular injury markers. Diabetes Obes Metab. https://doi.org/10.1111/dom.13301
doi: 10.1111/dom.13301
pubmed: 29573529
pmcid: 6055757
Iannantuoni F (2019) The SGLT2 inhibitor empagliflozin ameliorates the inflammatory profile in type 2 diabetic patients and promotes an antioxidant response in leukocytes. J Clin Med. https://doi.org/10.3390/jcm8111814
doi: 10.3390/jcm8111814
pubmed: 31683785
pmcid: 6912454
Sardu C (2021) Effects of sodium–glucose transporter 2 inhibitors (SGLT2-I) in patients with ischemic heart disease (IHD) treated by coronary artery bypass grafting via MiECC: inflammatory burden, and clinical outcomes at 5 years of follow-up. Front Pharmacol. https://doi.org/10.3389/fphar.2021.777083
doi: 10.3389/fphar.2021.777083
pubmed: 34867407
pmcid: 8634684
Grotta RL (2022) Anti-inflammatory effect of SGLT-2 inhibitors via uric acid and insulin. Cell Mol Life Sci. https://doi.org/10.1007/s00018-022-04289-z
doi: 10.1007/s00018-022-04289-z
pubmed: 35503137
pmcid: 9064844
Janic M (2022) Empagliflozin-metformin combination has antioxidative and anti-inflammatory properties that correlate with vascular protection in adults with type 1 diabetes. J Diabetes Res. https://doi.org/10.1155/2022/6796470
doi: 10.1155/2022/6796470
pubmed: 35620570
pmcid: 9130013
Koshino A, Schechter M, Sen T, Heerspink HJL (2022) Interleukin-6 and cardiovascular and kidney outcomes in patients with type 2 diabetes: new insights from CANVAS. Diabetes Care 45:2644–2652. https://doi.org/10.2337/figshare.20387259
doi: 10.2337/figshare.20387259
pubmed: 36134918
pmcid: 9862371
Hao Z (2022) Effects of canagliflozin and metformin on insulin resistance and visceral adipose tissue in people with newly-diagnosed type 2 diabetes. BMC Endocr Disord. https://doi.org/10.1186/s12902-022-00949-0
doi: 10.1186/s12902-022-00949-0
pubmed: 35144596
pmcid: 8830023
Nishimiya N, Tajima K, Imajo K et al (2021) Effects of canagliflozin on hepatic steatosis, visceral fat and skeletal muscle among patients with type 2 diabetes and non-alcoholic fatty liver disease. Intern Med. https://doi.org/10.2169/internalmedicine.7134-21
doi: 10.2169/internalmedicine.7134-21
pubmed: 33994437
pmcid: 8627812
Heerspink HJL (2019) Canagliflozin reduces inflammation and fibrosis biomarkers: a potential mechanism of action for beneficial effects of SGLT2 inhibitors in diabetic kidney disease. Diabetologia. https://doi.org/10.1007/s00125-019-4859-4
doi: 10.1007/s00125-019-4859-4
pubmed: 31001673
pmcid: 6560022
Bhavsar SK, Singh Y, Sharma P et al (2016) Expression of JAK3 sensitive Na+ coupled glucose carrier SGLT1 in activated cytotoxic T lymphocytes. Cell Physiol Biochem. https://doi.org/10.1159/000447827
doi: 10.1159/000447827
pubmed: 27595398
Xu C (2018) Canagliflozin exerts anti-inflammatory effects by inhibiting intracellular glucose metabolism and promoting autophagy in immune cells. Biochem Pharmacol. https://doi.org/10.1016/j.bcp.2018.03.013
doi: 10.1016/j.bcp.2018.03.013
pubmed: 30879494
pmcid: 6502225
Bonora BM, Cappellari R, Albiero M et al (2018) Effects of SGLT2 inhibitors on circulating stem and progenitor cells in patients with type 2 diabetes. J Clin Endocrinol Metab. https://doi.org/10.1210/jc.2018-00824
doi: 10.1210/jc.2018-00824
pubmed: 30113651
Koyani CN (2020) Empagliflozin protects heart from inflammation and energy depletion via AMPK activation. Pharmacol Res. https://doi.org/10.1016/j.phrs.2020.104870
doi: 10.1016/j.phrs.2020.104870
pubmed: 32434052
Lee N, Heo YJ, Choi S-E et al (2021) Anti-inflammatory effects of empagliflozin and gemigliptin on LPS-stimulated macrophage via the IKK/NF-κB, MKK7/JNK, and JAK2/STAT1 signalling pathways. J Immunol Res. https://doi.org/10.1155/2021/9944880
doi: 10.1155/2021/9944880
pubmed: 34541006
pmcid: 8445733
Borzouei S (2021) Changes in T helper cell-related factors in patients with type 2 diabetes mellitus after empagliflozin therapy. Hum Immunol. https://doi.org/10.1016/j.humimm.2021.03.004
doi: 10.1016/j.humimm.2021.03.004
pubmed: 33771372
Hess DA (2019) SGLT2 inhibition with empagliflozin increases circulating provascular progenitor cells in people with type 2 diabetes mellitus. Cell Metab 30:609–613. https://doi.org/10.1016/j.cmet.2019.08.015
doi: 10.1016/j.cmet.2019.08.015
pubmed: 31477497
Kim SR (2020) SGLT2 inhibition modulates NLRP3 inflammasome activity via ketones and insulin in diabetes with cardiovascular disease. Nat Commun. https://doi.org/10.1038/s41467-020-15983-6
doi: 10.1038/s41467-020-15983-6
pubmed: 33353950
pmcid: 7755909
Paroni R, Fermo I, Fiorina P, Cighetti G (2005) Determination of asymmetric and symmetric dimethylarginines in plasma of hyperhomocysteinemic subjects. Amino Acids. https://doi.org/10.1007/s00726-005-0191-z
doi: 10.1007/s00726-005-0191-z
pubmed: 15827687
La Rocca E, Fiorina P, Astorri E, Secchi A (2000) Patient survival and cardiovascular events after kidney-pancreas transplantation: comparison with kidney transplantation alone in uremic IDDM patients. Cell Transplant 9:929–932. https://doi.org/10.1177/096368970000900621
doi: 10.1177/096368970000900621
pubmed: 11202580